论文部分内容阅读
目的:探讨复方皂矾丸联合重组人粒细胞刺激因子注射液对白血病化疗后白细胞减少患者血清IL-6、IL-8及G-CSF水平的影响。方法:选取医院血液科诊断并治疗的白血病化疗后白细胞减少患者42例,按照随机数字表法分组,两组患者均给予常规治疗,对照组患者21例予以重组人粒细胞刺激因子注射液治疗,研究组患者21例予以复方皂凡丸联合重组人粒细胞刺激因子注射液治疗,采血测定治疗前后外周血像状况、血清IL-6、IL-8及G-CSF水平,同时对比临床疗效及不良反应状况。结果:对照组治疗有效率57.14%低于研究组治疗有效率85.71%,具有统计学意义(P<0.05);与对照组比较,研究组患者治疗后血红蛋白、白细胞及血小板水平均升高,治疗后血清IL-6、IL-8水平均降低,G-CSF水平均升高,具有统计学意义(P<0.05);对照组不良反应率为14.29%(3/21),研究组不良反应率为19.05%(4/21),两组间不良率无差异(P>0.05)。结论:复方皂凡丸联合重组人粒细胞刺激因子注射液能降低白血病化疗后白细胞降低患者血清IL-6、IL-8水平,升高G-CSF水平。
Objective: To investigate the effects of compound Zaofan Pills combined with recombinant human granulocyte-stimulating factor injection on the serum levels of IL-6, IL-8 and G-CSF in patients with leucopenia after leukemia chemotherapy. Methods: Forty-two patients with leukopenia after diagnosis and treatment of leukemia treated by hematology were randomly divided into two groups according to the random number table. The patients in the control group were treated with recombinant human granulocyte-stimulating factor injection. Twenty-one patients in the study group were given Zaofan Pills combined with recombinant human granulocyte-stimulating factor injection. Blood samples were collected before and after treatment to determine the level of serum IL-6, IL-8 and G-CSF, and to compare the clinical efficacy and adverse effects Reaction status. Results: Compared with the control group, the effective rate of treatment in the control group was 57.14% lower than that of the study group (85.71%), and the levels of hemoglobin, white blood cells and platelets in the study group were significantly increased after treatment The levels of IL-6 and IL-8 in serum were decreased and the levels of G-CSF in serum increased (P <0.05). The adverse reaction rate in control group was 14.29% (3/21). The adverse reaction rate 19.05% (4/21), no difference between the two groups (P> 0.05). CONCLUSION: Compound Zaofan Pills combined with recombinant human granulocyte-stimulating factor injection can reduce the serum levels of IL-6 and IL-8 and increase the level of G-CSF in patients with leucopenia after leukemia chemotherapy.